Cargando…
The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide.
Anti-tumour responses with CCRG81010, M & B 39565, NSC 353451, 8-carbamoyl-3-(2-chloroethyl)imidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one (Mitozolomide) in a panel of 4 murine colon tumours of varying growth characteristics and chemosensitivity and a spontaneous murine lymphoma are similar to those...
Autores principales: | Bibby, M. C., Double, J. A., Wahed, I. A., Hirbawi, N., Baker, T. G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1988
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246776/ https://www.ncbi.nlm.nih.gov/pubmed/3166903 |
Ejemplares similares
-
Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours.
por: Bibby, M. C., et al.
Publicado: (1981) -
Plasma and tissue disposition of mitozolomide in mice.
por: Brindley, C. J., et al.
Publicado: (1986) -
The effects of pretreatment of human tumour cells with MNNG on the DNA crosslinking and cytotoxicity of mitozolomide.
por: Gibson, N. W., et al.
Publicado: (1985) -
Phase II evaluation of mitozolomide in ovarian cancer.
por: Harding, M., et al.
Publicado: (1988) -
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent
por: Patterson, L H, et al.
Publicado: (2000)